The prevalence of opioid-related major potential drug-drug interactions and their impact on health care costs in chronic pain patients

Joseph V. Pergolizzi, Larry Ma, David R. Foster, Brian R. Overholser, Kevin M. Sowinski, Robert Taylor, Kent H. Summers

Research output: Contribution to journalArticle

Abstract

BACKGROUND: Literature has shown that chronic pain patients prescribed opioids are at an increased risk for experiencing drug-drug interactions as a result of polypharmacy. In addition, chronic, noncancer pain patients who experience drug-drug interactions have been shown to have greater health care utilization and costs. However, no study has focused on the health economics of major clinically significant drug-drug interactions associated with long-acting opioids. OBJECTIVES: To (a) estimate the prevalence of major drug-drug interactions among patients prescribed a long-acting opioid and (b) evaluate the potential impact of major drug-drug interactions on health care costs. METHODS: This study was a retrospective cohort analysis using claims data from the MarketScan Commercial Claims and Encounter Database between 2008 and 2010. Patients with at least 1 prescription for a longacting opioid for ≥30 days were placed into cohorts according to the expected clinical impact of the potential drug-drug interaction: major versus none. Propensity score matching was used to mitigate differences in baseline characteristics between the cohorts. Health care costs were based on payments for all covered health care services, which consisted of inpatient and outpatient medical, emergency department, and outpatient prescription costs. RESULTS: Among 57,752 chronic, noncancer pain patients who met all inclusion and exclusion criteria, 5.7% (3,302) were exposed to a potential major drug-drug interaction. The costs associated with a potential interaction versus no potential interaction were significantly more after baseline characteristics of the cohorts were normalized by propensity score matching. Monthly health care costs in the 90-day post-index period were significantly greater ($3,366 vs. $2,757, a $609 difference) in patients exposed to a potential drug-drug interaction of major clinical significance, compared with those not exposed to a drug-drug interaction. The higher health care costs were mainly driven by outpatient and inpatient medical costs. CONCLUSIONS: Exposure to potential drug-drug interactions may result in unnecessary and unintended health care costs. Physicians should be made aware of commonly administered cytochrome P450 (CYP450) metabolized drugs in the chronic pain patient and consider prescribing non-CYP450 metabolized opioid and nonopioid analgesics. Managed care's use of utilization management tools to avoid these exposures may reduce costs.

Original languageEnglish (US)
Pages (from-to)467-476
Number of pages10
JournalJournal of Managed Care Pharmacy
Volume20
Issue number5
StatePublished - 2014

Fingerprint

Drug interactions
Bioelectric potentials
Drug Interactions
Health care
Chronic Pain
Health Care Costs
Opioid Analgesics
Pharmaceutical Preparations
Costs
Costs and Cost Analysis
Propensity Score
Outpatients
Prescriptions
Inpatients
Patient Acceptance of Health Care
Non-Narcotic Analgesics
Polypharmacy
Managed Care Programs
Cytochrome P-450 Enzyme System
Health Services

ASJC Scopus subject areas

  • Pharmaceutical Science
  • Health Policy
  • Pharmacy
  • Medicine(all)

Cite this

Pergolizzi, J. V., Ma, L., Foster, D. R., Overholser, B. R., Sowinski, K. M., Taylor, R., & Summers, K. H. (2014). The prevalence of opioid-related major potential drug-drug interactions and their impact on health care costs in chronic pain patients. Journal of Managed Care Pharmacy, 20(5), 467-476.

The prevalence of opioid-related major potential drug-drug interactions and their impact on health care costs in chronic pain patients. / Pergolizzi, Joseph V.; Ma, Larry; Foster, David R.; Overholser, Brian R.; Sowinski, Kevin M.; Taylor, Robert; Summers, Kent H.

In: Journal of Managed Care Pharmacy, Vol. 20, No. 5, 2014, p. 467-476.

Research output: Contribution to journalArticle

Pergolizzi, JV, Ma, L, Foster, DR, Overholser, BR, Sowinski, KM, Taylor, R & Summers, KH 2014, 'The prevalence of opioid-related major potential drug-drug interactions and their impact on health care costs in chronic pain patients', Journal of Managed Care Pharmacy, vol. 20, no. 5, pp. 467-476.
Pergolizzi, Joseph V. ; Ma, Larry ; Foster, David R. ; Overholser, Brian R. ; Sowinski, Kevin M. ; Taylor, Robert ; Summers, Kent H. / The prevalence of opioid-related major potential drug-drug interactions and their impact on health care costs in chronic pain patients. In: Journal of Managed Care Pharmacy. 2014 ; Vol. 20, No. 5. pp. 467-476.
@article{25873515bce8428782ba435a5df1781d,
title = "The prevalence of opioid-related major potential drug-drug interactions and their impact on health care costs in chronic pain patients",
abstract = "BACKGROUND: Literature has shown that chronic pain patients prescribed opioids are at an increased risk for experiencing drug-drug interactions as a result of polypharmacy. In addition, chronic, noncancer pain patients who experience drug-drug interactions have been shown to have greater health care utilization and costs. However, no study has focused on the health economics of major clinically significant drug-drug interactions associated with long-acting opioids. OBJECTIVES: To (a) estimate the prevalence of major drug-drug interactions among patients prescribed a long-acting opioid and (b) evaluate the potential impact of major drug-drug interactions on health care costs. METHODS: This study was a retrospective cohort analysis using claims data from the MarketScan Commercial Claims and Encounter Database between 2008 and 2010. Patients with at least 1 prescription for a longacting opioid for ≥30 days were placed into cohorts according to the expected clinical impact of the potential drug-drug interaction: major versus none. Propensity score matching was used to mitigate differences in baseline characteristics between the cohorts. Health care costs were based on payments for all covered health care services, which consisted of inpatient and outpatient medical, emergency department, and outpatient prescription costs. RESULTS: Among 57,752 chronic, noncancer pain patients who met all inclusion and exclusion criteria, 5.7{\%} (3,302) were exposed to a potential major drug-drug interaction. The costs associated with a potential interaction versus no potential interaction were significantly more after baseline characteristics of the cohorts were normalized by propensity score matching. Monthly health care costs in the 90-day post-index period were significantly greater ($3,366 vs. $2,757, a $609 difference) in patients exposed to a potential drug-drug interaction of major clinical significance, compared with those not exposed to a drug-drug interaction. The higher health care costs were mainly driven by outpatient and inpatient medical costs. CONCLUSIONS: Exposure to potential drug-drug interactions may result in unnecessary and unintended health care costs. Physicians should be made aware of commonly administered cytochrome P450 (CYP450) metabolized drugs in the chronic pain patient and consider prescribing non-CYP450 metabolized opioid and nonopioid analgesics. Managed care's use of utilization management tools to avoid these exposures may reduce costs.",
author = "Pergolizzi, {Joseph V.} and Larry Ma and Foster, {David R.} and Overholser, {Brian R.} and Sowinski, {Kevin M.} and Robert Taylor and Summers, {Kent H.}",
year = "2014",
language = "English (US)",
volume = "20",
pages = "467--476",
journal = "Journal of managed care & specialty pharmacy",
issn = "2376-0540",
publisher = "Academy of Managed Care Pharmacy (AMCP)",
number = "5",

}

TY - JOUR

T1 - The prevalence of opioid-related major potential drug-drug interactions and their impact on health care costs in chronic pain patients

AU - Pergolizzi, Joseph V.

AU - Ma, Larry

AU - Foster, David R.

AU - Overholser, Brian R.

AU - Sowinski, Kevin M.

AU - Taylor, Robert

AU - Summers, Kent H.

PY - 2014

Y1 - 2014

N2 - BACKGROUND: Literature has shown that chronic pain patients prescribed opioids are at an increased risk for experiencing drug-drug interactions as a result of polypharmacy. In addition, chronic, noncancer pain patients who experience drug-drug interactions have been shown to have greater health care utilization and costs. However, no study has focused on the health economics of major clinically significant drug-drug interactions associated with long-acting opioids. OBJECTIVES: To (a) estimate the prevalence of major drug-drug interactions among patients prescribed a long-acting opioid and (b) evaluate the potential impact of major drug-drug interactions on health care costs. METHODS: This study was a retrospective cohort analysis using claims data from the MarketScan Commercial Claims and Encounter Database between 2008 and 2010. Patients with at least 1 prescription for a longacting opioid for ≥30 days were placed into cohorts according to the expected clinical impact of the potential drug-drug interaction: major versus none. Propensity score matching was used to mitigate differences in baseline characteristics between the cohorts. Health care costs were based on payments for all covered health care services, which consisted of inpatient and outpatient medical, emergency department, and outpatient prescription costs. RESULTS: Among 57,752 chronic, noncancer pain patients who met all inclusion and exclusion criteria, 5.7% (3,302) were exposed to a potential major drug-drug interaction. The costs associated with a potential interaction versus no potential interaction were significantly more after baseline characteristics of the cohorts were normalized by propensity score matching. Monthly health care costs in the 90-day post-index period were significantly greater ($3,366 vs. $2,757, a $609 difference) in patients exposed to a potential drug-drug interaction of major clinical significance, compared with those not exposed to a drug-drug interaction. The higher health care costs were mainly driven by outpatient and inpatient medical costs. CONCLUSIONS: Exposure to potential drug-drug interactions may result in unnecessary and unintended health care costs. Physicians should be made aware of commonly administered cytochrome P450 (CYP450) metabolized drugs in the chronic pain patient and consider prescribing non-CYP450 metabolized opioid and nonopioid analgesics. Managed care's use of utilization management tools to avoid these exposures may reduce costs.

AB - BACKGROUND: Literature has shown that chronic pain patients prescribed opioids are at an increased risk for experiencing drug-drug interactions as a result of polypharmacy. In addition, chronic, noncancer pain patients who experience drug-drug interactions have been shown to have greater health care utilization and costs. However, no study has focused on the health economics of major clinically significant drug-drug interactions associated with long-acting opioids. OBJECTIVES: To (a) estimate the prevalence of major drug-drug interactions among patients prescribed a long-acting opioid and (b) evaluate the potential impact of major drug-drug interactions on health care costs. METHODS: This study was a retrospective cohort analysis using claims data from the MarketScan Commercial Claims and Encounter Database between 2008 and 2010. Patients with at least 1 prescription for a longacting opioid for ≥30 days were placed into cohorts according to the expected clinical impact of the potential drug-drug interaction: major versus none. Propensity score matching was used to mitigate differences in baseline characteristics between the cohorts. Health care costs were based on payments for all covered health care services, which consisted of inpatient and outpatient medical, emergency department, and outpatient prescription costs. RESULTS: Among 57,752 chronic, noncancer pain patients who met all inclusion and exclusion criteria, 5.7% (3,302) were exposed to a potential major drug-drug interaction. The costs associated with a potential interaction versus no potential interaction were significantly more after baseline characteristics of the cohorts were normalized by propensity score matching. Monthly health care costs in the 90-day post-index period were significantly greater ($3,366 vs. $2,757, a $609 difference) in patients exposed to a potential drug-drug interaction of major clinical significance, compared with those not exposed to a drug-drug interaction. The higher health care costs were mainly driven by outpatient and inpatient medical costs. CONCLUSIONS: Exposure to potential drug-drug interactions may result in unnecessary and unintended health care costs. Physicians should be made aware of commonly administered cytochrome P450 (CYP450) metabolized drugs in the chronic pain patient and consider prescribing non-CYP450 metabolized opioid and nonopioid analgesics. Managed care's use of utilization management tools to avoid these exposures may reduce costs.

UR - http://www.scopus.com/inward/record.url?scp=84898950949&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84898950949&partnerID=8YFLogxK

M3 - Article

C2 - 24761818

AN - SCOPUS:84898950949

VL - 20

SP - 467

EP - 476

JO - Journal of managed care & specialty pharmacy

JF - Journal of managed care & specialty pharmacy

SN - 2376-0540

IS - 5

ER -